Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1872-3128
  • E-ISSN: 1874-0758

Abstract

Background: Carbon-carbon bond cleavage of a saturated aliphatic moiety is rarely seen in xenobiotic metabolism. Olanexidine (Olanedine®), containing an n-octyl (C) side chain, was mainly metabolized to various shortened side chain (C to C) acid-containing metabolites in vivo in preclinical species. In liver microsomes and S9, the major metabolites of olanexidine were from multi-oxidation on its n-octyl (C) side chain. However, the carbon-carbon bond cleavage mechanism of n-octyl (C) side chain, and enzyme(s) responsible for its metabolism in human remained unknown. Methods: A pair of regioisomers of α-ketol-containing C side chain olanexidine analogs (3,2-ketol olanexidine and 2,3-ketol olanexidine) were synthesized, followed by incubation in human liver microsomes, recombinant human cytochrome P450 enzymes or human hepatocytes, and subsequent metabolite identification using LC/UV/MS. Results: Multiple shortened side chain (C to C) metabolites were identified, including C, C and C- acid and C-hydroxyl metabolites. Among 19 cytochrome P450 enzymes tested, CYP2D6, CYP3A4 and CYP3A5 were identified to catalyze carbon-carbon bond cleavage. Conclusion: 3,2-ketol olanexidine and 2,3-ketol olanexidine were confirmed as the key intermediates in carbon-carbon bond cleavage. Its mechanism is proposed that a nucleophilic addition of iron-peroxo species, generated by CYP2D6 and CYP3A4/5, to the carbonyl group caused the carbon-carbon bond cleavage between the adjacent hydroxyl and ketone groups. As results, 2,3-ketol olanexidine formed a C side chain acid metabolite. While, 3,2-ketol olanexidine formed a C side chain aldehyde intermediate, which was either oxidized to a C side chain acid metabolite or reduced to a C side chain hydroxyl metabolite.

Loading

Article metrics loading...

/content/journals/dml/10.2174/1872312813666191125095818
2021-03-01
2025-07-07
Loading full text...

Full text loading...

/content/journals/dml/10.2174/1872312813666191125095818
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test